Tuesday, August 5, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Next-generation treatments hitch a ride into cancer cells

April 16, 2024
in Cancer
Reading Time: 5 mins read
0
Fig. 1
66
SHARES
600
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT
ADVERTISEMENT

Osaka, Japan – Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes. In people with cancer, ASOs have the potential to block messages that encourage the growth and spread of the tumor. However, ASOs aren’t used for treating cancer yet. They must first get delivered inside cancer cells, but the cancer cells won’t let them in.

Finding an effective ASO delivery system is a major challenge. Cancer cells have gatekeeper molecules that stop unwanted substances from entering. Although investigators have tried many ways of getting ASOs past the gatekeepers, success has been limited.

Now, in a study recently published in the journal Nucleic Acids Research, researchers from Osaka University have discovered a way to deliver ASOs to their targets inside cancer cells. The team synthesized a new compound, named L687, which opens specific calcium permeable channels on the surface of cancer cells. When the calcium flows into cells through the open channels it tells the cells to let in the ASOs.

“We discovered that we could selectively activate the TRPC3/C6 calcium permeable channels1) with the activator L687,” explains lead author Hiroto Kohashi. “We then found that combination treatment with L687 and ASO promoted efficient uptake of ASO into cancer cells during laboratory tests and tumor cells inside the mouse. As a result, target gene activity was suppressed and ASO efficacy was enhanced.”

Until now, ASOs have mainly been used to treat incurable diseases and had to be delivered into the liver or spinal fluid. According to the Osaka team’s research, L687 is an effective drug delivery system that may extend the benefits of ASO treatment to other parts of the body.

“We hope that the results of our research will lead to significant progress in the development and delivery of ASOs and similar gene-targeting drugs for treating cancer,” says senior author Masahito Shimojo.

The team believes that L687 could be a particularly effective way of delivering ASO therapy to lung or prostate cancers. These cancers have many TRPC3/C6 calcium permeable channels1) that can be opened by L687, potentially revealing new targets for these next-generation therapies.

1) TRPC3/C6 channels belong to a Transient Receptor Potential Canonical (TRPC) Channel subfamily of a TRP channel superfamily.

###
The article, “A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides,” was published in Nucleic Acids Research at DOI: https://doi.org/10.1093/nar/gkae245.

 

Fig. 1

Credit: 2024 Nagata et al., A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides., Nucleic Acids Research

Osaka, Japan – Antisense oligonucleotides (ASOs) are next-generation drugs that can treat disease by blocking the transfer of harmful messages from our genes. In people with cancer, ASOs have the potential to block messages that encourage the growth and spread of the tumor. However, ASOs aren’t used for treating cancer yet. They must first get delivered inside cancer cells, but the cancer cells won’t let them in.

Finding an effective ASO delivery system is a major challenge. Cancer cells have gatekeeper molecules that stop unwanted substances from entering. Although investigators have tried many ways of getting ASOs past the gatekeepers, success has been limited.

Now, in a study recently published in the journal Nucleic Acids Research, researchers from Osaka University have discovered a way to deliver ASOs to their targets inside cancer cells. The team synthesized a new compound, named L687, which opens specific calcium permeable channels on the surface of cancer cells. When the calcium flows into cells through the open channels it tells the cells to let in the ASOs.

“We discovered that we could selectively activate the TRPC3/C6 calcium permeable channels1) with the activator L687,” explains lead author Hiroto Kohashi. “We then found that combination treatment with L687 and ASO promoted efficient uptake of ASO into cancer cells during laboratory tests and tumor cells inside the mouse. As a result, target gene activity was suppressed and ASO efficacy was enhanced.”

Until now, ASOs have mainly been used to treat incurable diseases and had to be delivered into the liver or spinal fluid. According to the Osaka team’s research, L687 is an effective drug delivery system that may extend the benefits of ASO treatment to other parts of the body.

“We hope that the results of our research will lead to significant progress in the development and delivery of ASOs and similar gene-targeting drugs for treating cancer,” says senior author Masahito Shimojo.

The team believes that L687 could be a particularly effective way of delivering ASO therapy to lung or prostate cancers. These cancers have many TRPC3/C6 calcium permeable channels1) that can be opened by L687, potentially revealing new targets for these next-generation therapies.

1) TRPC3/C6 channels belong to a Transient Receptor Potential Canonical (TRPC) Channel subfamily of a TRP channel superfamily.

###
The article, “A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides,” was published in Nucleic Acids Research at DOI: https://doi.org/10.1093/nar/gkae245.

 

About Osaka University
Osaka University was founded in 1931 as one of the seven imperial universities of Japan and is now one of Japan’s leading comprehensive universities with a broad disciplinary spectrum. This strength is coupled with a singular drive for innovation that extends throughout the scientific process, from fundamental research to the creation of applied technology with positive economic impacts. Its commitment to innovation has been recognized in Japan and around the world, being named Japan’s most innovative university in 2015 (Reuters 2015 Top 100) and one of the most innovative institutions in the world in 2017 (Innovative Universities and the Nature Index Innovation 2017). Now, Osaka University is leveraging its role as a Designated National University Corporation selected by the Ministry of Education, Culture, Sports, Science and Technology to contribute to innovation for human welfare, sustainable development of society, and social transformation.
Website:

 



Journal

Nucleic Acids Research

DOI

10.1093/nar/gkae245

Method of Research

Experimental study

Subject of Research

Animals

Article Title

A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides

Article Publication Date

16-Apr-2024

Share26Tweet17
Previous Post

Australian media need generative AI policies to help navigate misinformation and disinformation

Next Post

Multiple pollutants from crop and livestock production in the Yangtze River: status and challenges

Related Posts

blank
Cancer

Computational Biology Designs Custom Binders to Outsmart Cancer

August 5, 2025
blank
Cancer

‘Sweet’ Breakthrough Uncovers How Glucose Powers Cancer-Fighting Immune Cells

August 5, 2025
blank
Cancer

Carnosol’s Cancer Fight: From Molecules to Medicine

August 5, 2025
blank
Cancer

48th Annual UNC Lineberger Scientific Symposium Highlights Advances in Cancer Discovery and Patient Care

August 5, 2025
blank
Cancer

Chronic CMV Infection Boosts Melanoma Immunotherapy Survival

August 5, 2025
blank
Cancer

Carvedilol Boosts Paclitaxel Effect in Resistant Gastric Cancer

August 5, 2025
Next Post
Graphical abstract

Multiple pollutants from crop and livestock production in the Yangtze River: status and challenges

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27530 shares
    Share 11009 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    941 shares
    Share 376 Tweet 235
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    506 shares
    Share 202 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Urban Rituals Halted: COVID-19 Lockdowns Impact Celebrations
  • Canadian Parents’ Views on Micro- and Nanoplastics
  • Unveiling NUDIX Hydrolase in Leishmania major
  • Computational Biology Designs Custom Binders to Outsmart Cancer

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,184 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading